Dr. Martens's revenue for the
six
months ended in Mar. 2026 was £442.9 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was £764.9 Mil.
Dr. Martens's Revenue per Share for the
six
months ended in Mar. 2026 was £0.46.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was £0.78.
Warning Sign:
Dr. Martens PLC revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Dr. Martens was -3.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -7.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -1.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 9 years, Dr. Martens's highest 3-Year average Revenue per Share Growth Rate was 30.40% per year. The lowest was -7.90% per year. And the median was 9.45% per year.
Dr. Martens (CHIX:DOCSl) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Dr. Martens Revenue Related Terms
Dr. Martens Revenue Historical Data
* Premium members only.
The historical data trend for Dr. Martens's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Footwear & Accessories subindustry, Dr. Martens's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr. Martens Revenue vs Manufacturing - Apparel & Accessories Industry
For the Manufacturing - Apparel & Accessories industry and Consumer Cyclical sector, Dr. Martens's Revenue distribution charts can be found below:
* The bar in red indicates where Dr. Martens's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was £764.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr. Martens (CHIX:DOCSL) has a Revenue of £764.9 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Dr. Martens and its competitors.
Is Dr. Martens' Revenue too high?
Dr. Martens' current Revenue is £764.9 Mil. Overall, Dr. Martens has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dr. Martens' Revenue compare to NKE and DECK?
Dr. Martens' Revenue of £764.9 Mil can be compared against companies in the Manufacturing - Apparel & Accessories industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Manufacturing - Apparel & Accessories company?
A good Revenue depends on the Manufacturing - Apparel & Accessories industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Dr. Martens and its competitors. Dr. Martens's current Revenue is £764.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Martens stock overvalued right now?
Based on GuruFocus' analysis, Dr. Martens (CHIX:DOCSL) is currently considered Fairly Valued. The stock's GF Value™ is £0.72, compared to a current price of £0.72 — trading 0.1% above its estimated fair value. The current Revenue is £764.9 Mil. Dr. Martens' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Dr. Martens (CHIX:DOCSL), the current Revenue is £764.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr. Martens (CHIX:DOCSL) Overvalued in 2026?
Based on GuruFocus' analysis, Dr. Martens stock appears to be overvalued.
The current stock price of £0.72 is trading 0.1% above its estimated GF Value™ of £0.72.
GuruFocus considers Dr. Martens to be Fairly Valued.
Key valuation signals for CHIX:DOCSL:
Revenue: £764.9 Mil
GF Value™: £0.72 vs. price of £0.72 (0.1% above fair value)
No single metric tells the full story. See the CHIX:DOCSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Martens PLC is engaged in the footwear business. Its product segments include Originals, Fusion, Kids and Casual, and a complementary range of Accessories. The company has sales through E-commerce, Retail, and Wholesale of Products. Geographically, it derives the majority of its revenue from EMEA and has a presence in the Americas and APAC.
52GF Score
Get the complete analysis for CHIX:DOCSL
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DOCSL has been successfully added to your 
